Teaching a new mouse old tricks: Humanized mice as an infection model for Variola virus
Authors:
- Christina L. HutsonCHChristina L. Hutson
- Ashley V. KondasAKAshley V. Kondas
- Jana M. RitterJRJana M. Ritter
- Zachary ReedZRZachary Reed
- Clint N. MorganCMClint N. Morgan
- Matthew R. MauldinMMMatthew R. Mauldin
- Johanna S. SalzerJSJohanna S. Salzer
- Christine M. HughesCHChristine M. Hughes
- Cynthia S. GoldsmithCGCynthia S. Goldsmith
Open Access
- 21 September 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 17 (9) , e1009633
Abstract
Smallpox, caused by the solely human pathogen Variola virus (VARV), was declared eradicated in 1980. While known VARV stocks are secure, smallpox remains a bioterrorist threat agent. Recent U.S. Food and Drug Administration approval of the first smallpox anti-viral (tecovirimat) therapeutic was a successful step forward in smallpox preparedness; however, orthopoxviruses can become resistant to treatment, suggesting a multi-therapeutic approach is necessary. Animal models are required for testing medical countermeasures (MCMs) and ideally MCMs are tested directly against the pathogen of interest. Since VARV only infects humans, a representative animal model for testing therapeutics directly against VARV remains a challenge. Here we show that three different humanized mice strains are highly susceptible to VARV infection, establishing the first small animal model using VARV. In comparison, the non-humanized, immunosuppressed background mouse was not susceptible to systemic VARV infection. Following an intranasal VARV challenge that mimics the natural route for human smallpox transmission, the virus spread systemically within the humanized mouse before mortality (~ 13 days post infection), similar to the time from exposure to symptom onset for ordinary human smallpox. Our identification of a permissive/representative VARV animal model can facilitate testing of MCMs in a manner consistent with their intended use. Preparedness activities against highly transmissible respiratory viruses with high mortality have been highlighted during the ongoing COVID-19 pandemic. Smallpox, caused by Variola virus (VARV) infection, is highly transmissible and estimated to have killed 300 million people in the 20th century alone with ~30% mortality. Through an intensive vaccination campaign smallpox was declared eradicated in 1980 and routine smallpox vaccination of individuals ceased. Today’s population has little/no immunity against VARV; if smallpox were to re-emerge the worldwide results would be devastating. Development of antiviral strategies is critical for outbreak response efforts and in order to truly gauge the potential effectiveness of a medical countermeasure (MCM), it must be tested directly against the pathogen. VARV is solely a human pathogen and infections of surrogate animal models have been largely unsuccessful. Here we use the humanized mouse to establish the first small animal model using VARV. We found that the virus spread systemically within humanized mice before mortality (~ 13 days post infection), similar to the time from exposure to symptom onset for ordinary human smallpox. These findings improve upon current MCM efficacy testing methods by providing a means to conduct in vivo evaluations of smallpox MCMs directly against VARV.Keywords
Funding Information
- Biomedical Advanced Research and Development Authority
This publication has 57 references indexed in Scilit:
- The Vaccinia Virus O1 Protein Is Required for Sustained Activation of Extracellular Signal-Regulated Kinase 1/2 and Promotes Viral VirulenceJournal of Virology, 2012
- Progression of Pathogenic Events in Cynomolgus Macaques Infected with Variola VirusPLOS ONE, 2011
- Humoral immune responses in humanized BLT mice immunized with West Nile virus and HIV-1 envelope proteins are largely mediated via human CD5+ B cellsImmunology, 2011
- Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: Pathogenesis, prophylaxis, and antiviral therapyVirology, 2011
- Identification of Wild-Derived Inbred Mouse Strains Highly Susceptible to Monkeypox Virus Infection for Use as Small Animal ModelsJournal of Virology, 2010
- Poxvirus Proteomics and Virus-Host Protein InteractionsMicrobiology and Molecular Biology Reviews, 2009
- Nonhuman Primates Are Protected from Smallpox Virus or Monkeypox Virus Challenges by the Antiviral Drug ST-246Antimicrobial Agents and Chemotherapy, 2009
- Creation of “Humanized” Mice to Study Human ImmunityCurrent Protocols in Immunology, 2008
- Identification of Hot Spots in the Variola Virus Complement Inhibitor (SPICE) for Human Complement RegulationJournal of Virology, 2008
- Synergistic Efficacy of the Combination of ST-246 with CMX001 against OrthopoxvirusesAntimicrobial Agents and Chemotherapy, 2007